Company intelligence / Profile preview
Cosmo Pharmaceuticals
- Ownership
- Public · COPN
- Employees
- ~325
- Development stage
- Commercial
Overview
Cosmo has successfully developed, obtained regulatory approval for, and commercialized several drugs targeting gastrointestinal diseases and dermatology. Its proprietary MMX® technology enables targeted drug delivery in the colon. The company also markets AI-powered medical devices like GI Genius™ to assist clinicians during colonoscopy. Products such as Lialda®, Uceris®, Aemcolo®, Winlevi®, Eleview®, Lumeblue® are approved in major markets. Recent clinical results include positive Phase III data for Methylene Blue MMX®.
- Therapeutic areas
- GastroenterologyDermatologyOncologyInfectious Diseases
- Modalities
- Small moleculesMedical devices
- Industry
- Biotech
Drug pipeline
10 assets9 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $29.2M
- Total revenue
- $65.3M
- Enterprise value
- $43.3M
Beyond the preview
Go deeper on Cosmo Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cosmo Pharmaceuticals.